HR+/HER2- was the most commonly diagnosed subtype (41.1%) among AYA breast cancer patients, followed by triple-negative (19.0%), HR+/HER2+ (15.2%), and HR-/HER2+ (8.8%) (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.